Spero Therapeutics Inc is a pharmaceutical company that focuses on developing novel treatments for serious infections. The company's corporate philosophy is centered around innovation, collaboration, and patient-centricity. By embracing cutting-edge science and fostering collaborations with leading researchers, Spero Therapeutics Inc aims to address the significant unmet medical needs in the field of infectious diseases. Their values include a commitment to scientific excellence, dedication to patient well-being, and a passion for improving global public health. Through their research and development efforts, Spero Therapeutics Inc strives to make a positive impact on the lives of patients and revolutionize the treatment landscape for infectious diseases.

Spero Therapeutics Inc is primarily present in the United States.

Spero Therapeutics Inc, a leading biopharmaceutical company, has achieved remarkable milestones in its journey. The company successfully completed a Phase 1 clinical trial for its novel product candidate, SPR206, designed to combat multi-drug resistant infections. Additionally, Spero Therapeutics Inc received a contract from the Biomedical Advanced Research and Development Authority (BARDA) for the development of SPR720, an oral antibiotic. These accomplishments reinforce Spero Therapeutics Inc's commitment to addressing unmet medical needs and delivering innovative solutions for patients. Through their unwavering dedication and cutting-edge research, Spero Therapeutics Inc continues to make substantial strides in the field of antibacterial therapy.

Spero Therapeutics Inc is a pharmaceutical company focused on developing novel treatments for drug-resistant bacterial infections. Founded in 2013, the company is headquartered in Cambridge, Massachusetts. Spero Therapeutics is dedicated to addressing the urgent global need for effective antibiotics, as the rise of antibiotic resistance has become a major public health concern. The company utilizes its proprietary platform to identify and develop potent drugs that target a wide range of bacteria. By harnessing innovative science and advanced research, Spero Therapeutics aims to provide hope for patients suffering from serious and life-threatening infections.

Some of the main competitors of Spero Therapeutics Inc in the market include biopharmaceutical companies like Merck & Co., Inc., Pfizer Inc., and GlaxoSmithKline plc. These competitors are also engaged in researching and developing innovative therapies for infectious diseases, with a focus on combating drug-resistant bacteria.

Spero Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Spero Therapeutics Inc is centered around developing and commercializing novel treatments for multi-drug-resistant bacterial infections. They aim to address the urgent need for new antibiotics to combat the growing threat of antibiotic resistance. Spero Therapeutics Inc utilizes its platform, including its proprietary Potentiator Platform, to discover and design potential drugs that can enhance the therapeutic efficacy of existing antibiotics and overcome resistance mechanisms. By focusing on serious bacterial infections that have limited treatment options, Spero Therapeutics Inc strives to provide better healthcare solutions for patients in need.

Količnik cena/dobiček trenutno ni mogoče izračunati za Spero Therapeutics.

KUV za Spero Therapeutics trenutno ni mogoče izračunati.

AlleAktien Qualitätsscore trenutno ne more biti izračunan za Spero Therapeutics.

Prihodki trenutno ne morejo biti izračunani za Spero Therapeutics.

Dobička trenutno ni mogoče izračunati za Spero Therapeutics.

Spero Therapeutics Inc. is a biopharmaceutical company focused on the development of new antibiotics to combat antibiotic resistance. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Spero Therapeutics izplača dividendo v višini 0 USD, razdeljeno na izplačil letno.

Dividende za Spero Therapeutics trenutno ni mogoče izračunati ali pa podjetje ne izplačuje dividend.

ISIN od Spero Therapeutics je US84833T1034.

WKN od Spero Therapeutics je A2H63F.

Oznaka delnice Spero Therapeutics je SPRO.

V zadnjih 12 mesecih je Spero Therapeutics izplačal dividendo v višini . To ustreza približni donosnosti dividend . V prihajajočih 12 mesecih bo Spero Therapeutics predvidoma izplačal dividendo v višini 0 USD.

Trenutni donos od dividend za Spero Therapeutics znaša .

Spero Therapeutics izplačuje četrtletno dividendo. Ta se izplačuje v mesecih april, april, julij, oktober.

Spero Therapeutics je v zadnjih 0 letih vsako leto izplačeval dividend.

V naslednjih 12 mesecih se pričakuje dividende v višini 0 USD. To ustreza dividendnemu donosu 0 %.

Spero Therapeutics je razvrščen v sektor 'Zdravje'.

Da si prejel zadnjo dividendo Spero Therapeutics z dne 7. 10. 2015 v višini 0,015 USD, si moral imeti delnico v depoju pred dnevom brez pravice do dividende (Ex-Tag) 16. 9. 2015.

Zadnje izplačilo dividende je bilo 7. 10. 2015.

V letu 2023 je Spero Therapeutics 0 USD izplačal kot dividende.

Dividende od Spero Therapeutics se izplačujejo v USD.